.jpg "Margaret V. Ragni, MD MPH photo")
Professor of Medicine & Clinical & Translational Research
Division Hematology/ Oncology - University of Pittsburgh
Pittsburgh, United States
Margaret V. Ragni, M.D., M.P.H.
Brief Biography
Dr. Ragni is a Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh, involved in clinical care and cutting edge clinical translational research in congenital hemostatic and thrombotic disorders. She has served as the chair of clinical trials, prospective epidemiologic, observational, case-control studies, cost-effectiveness analyses, and investigator-initiated new drug trials in hemophilia and VWD. Her studies were among the first multi-center NIH-funded investigator-initiated studies in hemophilia and VWD. Most recently she heads the NHLBI-funded multi-center VWDMin Trial to minimize menorrhagia; the HRSA-funded INHIBIT Trials; and the Takeda-funded Investigator-Initiated VWD-Woman Trial to prevent postpartum hemorrhage. She served as Co-Chair for the 2021 NHF Resources Working Group, and 2022 NHF Infrastructure Working Group for the Bleeding Disorders Research Blueprint, and also served as Subcommittee Co-Chair of the 2018 NHLBI State of the Science NHLBI SOS to design clinical trials for individuals with bleeding disorders. She is the Medical Director of the Hemophilia Center of Western PA and served as a 30-year member of the National Hemophilia Foundation Medical & Scientific Advisory Committee (MASAC). She is also a member of the ASH Maternal Health in Hematology Committee, an Associate Editor of the ASH online journal Blood Advances, and serves as a mentor to students, residents, and fellows in clinical translational research.